| Item Type | Name |
|
Academic Article
|
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
|
|
Academic Article
|
"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
|
|
Academic Article
|
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
|
|
Academic Article
|
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
|
|
Academic Article
|
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
|
|
Academic Article
|
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
|
|
Academic Article
|
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
|
|
Academic Article
|
Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
|
|
Academic Article
|
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
|
|
Academic Article
|
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
|
|
Academic Article
|
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
|
|
Academic Article
|
Atezolizumab for the treatment of breast cancer.
|
|
Academic Article
|
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
|
|
Academic Article
|
Novel therapies for triple-negative breast cancer.
|
|
Academic Article
|
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
|
|
Academic Article
|
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
|
|
Academic Article
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
|
|
Academic Article
|
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
|
|
Academic Article
|
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
|
|
Academic Article
|
Clinical trials of immunotherapy in triple-negative breast cancer.
|
|
Academic Article
|
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
|
|
Academic Article
|
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
|
|
Academic Article
|
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
|
|
Concept
|
Triple Negative Breast Neoplasms
|
|
Academic Article
|
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
|
|
Academic Article
|
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
|
|
Academic Article
|
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
|
|
Academic Article
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
|
|
Academic Article
|
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
|